Lung Cancer Staging: Imaging and Potential Pitfalls.
Lauren T ErasmusTaylor A StrangeRishi AgrawalChad D StrangeJitesh AhujaGirish S ShroffMylene T TruongPublished in: Diagnostics (Basel, Switzerland) (2023)
Lung cancer is the leading cause of cancer deaths in men and women in the United States. Accurate staging is needed to determine prognosis and devise effective treatment plans. The International Association for the Study of Lung Cancer (IASLC) has made multiple revisions to the tumor, node, metastasis (TNM) staging system used by the Union for International Cancer Control and the American Joint Committee on Cancer to stage lung cancer. The eighth edition of this staging system includes modifications to the T classification with cut points of 1 cm increments in tumor size, grouping of lung cancers associated with partial or complete lung atelectasis or pneumonitis, grouping of tumors with involvement of a main bronchus regardless of distance from the carina, and upstaging of diaphragmatic invasion to T4. The N classification describes the spread to regional lymph nodes and no changes were proposed for TNM-8. In the M classification, metastatic disease is divided into intra- versus extrathoracic metastasis, and single versus multiple metastases. In order to optimize patient outcomes, it is important to understand the nuances of the TNM staging system, the strengths and weaknesses of various imaging modalities used in lung cancer staging, and potential pitfalls in image interpretation.
Keyphrases
- lymph node
- papillary thyroid
- pet ct
- deep learning
- machine learning
- high resolution
- squamous cell
- neoadjuvant chemotherapy
- small cell lung cancer
- childhood cancer
- squamous cell carcinoma
- mass spectrometry
- lymph node metastasis
- photodynamic therapy
- cell migration
- early stage
- health insurance
- climate change
- replacement therapy
- systemic sclerosis